Showing 18,221 - 18,240 results of 105,033 for search '(( 10 ((we decrease) OR (nn decrease)) ) OR ( 100 ((ng decrease) OR (a decrease)) ))', query time: 1.20s Refine Results
  1. 18221

    DataSheet_1_A novel gene SpCTP3 from the hyperaccumulator Sedum plumbizincicola redistributes cadmium and increases its accumulation in transgenic Populus × canescens.docx by Shaocui Li (14584802)

    Published 2023
    “…Our results suggest that overexpressing SpCTP3 in transgenic poplar plants promotes Cd accumulation, modulates Cd distribution and ROS homeostasis, and decreases Cd toxicity via organic acids. In conclusion, genetically modifying plants to overexpress SpCTP3 may be a viable strategy for improving the phytoremediation of Cd-polluted soil.…”
  2. 18222

    Video_3_Kinesiophobia Severity Categories and Clinically Meaningful Symptom Change in Persons With Achilles Tendinopathy in a Cross-Sectional Study: Implications for Assessment and... by Ruth L. Chimenti (10939173)

    Published 2021
    “…Half of respondents considered a 5-min (35% of sample) or 10-min (16%) decrease in morning stiffness as clinically meaningful.…”
  3. 18223

    Video_2_Kinesiophobia Severity Categories and Clinically Meaningful Symptom Change in Persons With Achilles Tendinopathy in a Cross-Sectional Study: Implications for Assessment and... by Ruth L. Chimenti (10939173)

    Published 2021
    “…Half of respondents considered a 5-min (35% of sample) or 10-min (16%) decrease in morning stiffness as clinically meaningful.…”
  4. 18224

    Video_4_Kinesiophobia Severity Categories and Clinically Meaningful Symptom Change in Persons With Achilles Tendinopathy in a Cross-Sectional Study: Implications for Assessment and... by Ruth L. Chimenti (10939173)

    Published 2021
    “…Half of respondents considered a 5-min (35% of sample) or 10-min (16%) decrease in morning stiffness as clinically meaningful.…”
  5. 18225

    Video_1_Kinesiophobia Severity Categories and Clinically Meaningful Symptom Change in Persons With Achilles Tendinopathy in a Cross-Sectional Study: Implications for Assessment and... by Ruth L. Chimenti (10939173)

    Published 2021
    “…Half of respondents considered a 5-min (35% of sample) or 10-min (16%) decrease in morning stiffness as clinically meaningful.…”
  6. 18226
  7. 18227

    Scaling of Convex Hull Volume to Body Mass in Modern Primates, Non-Primate Mammals and Birds by Charlotte A. Brassey (499316)

    Published 2014
    “…Results suggest non-primate mammals scale body mass to <i>vol</i><sub>CH</sub> isometrically (<i>b</i> = 0.92, 95%CI = 0.85–1.00, <i>p</i> = 0.08). Birds scale body mass to <i>vol</i><sub>CH</sub> with negative allometry (<i>b</i> = 0.81, 95%CI = 0.70–0.91, <i>p</i> = 0.011) and apparent density (<i>vol</i><sub>CH</sub>/<i>M</i><sub>b</sub>) therefore decreases with mass (<i>r</i><sup>2</sup> = 0.36, <i>p</i><0.05). …”
  8. 18228

    Loss of protein stability in the absence of myotubularin-MTMR12 interactions. by Vandana A. Gupta (142475)

    Published 2013
    “…<p>(A) Knockdown of <i>mtmr12</i> resulted in a strong decrease of myotubularin protein in <i>mtmr12</i> morphant zebrafish at 3 dpf by western blotting. …”
  9. 18229

    XBP1 signalling is essential for alleviating mutant protein aggregation in ER-stress related skeletal disease - Fig 3 by Katarzyna A. Piróg (490536)

    Published 2019
    “…<i>Xbp1</i> null cartilage showed a 16% decrease in proliferation compared to the wild type control. …”
  10. 18230

    Zn<sup>2+</sup> is required for the enhancement of NMDAR fEPSPS which requires NR2B-containing NMDARs and activation of Src family kinases (SFK). by John A. Sullivan (6018725)

    Published 2018
    “…<b>(B)</b> Summary of NMDAR fEPSP decrease versus baseline (100%) after 70 minutes drug application in slices treated with 1μM Ro25-6981 and those treated with Ro25-6981 plus 1μM ZnCl<sub>2</sub> (<i>P</i>>0.05; Student’s t-test). …”
  11. 18231

    Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer by Jeffrey A. Meyerhardt (158559)

    Published 2012
    “…Vandetanib and cetuximab treatment induced a sustained increase in plasma PlGF and a transient decrease in plasma sVEGFR1, but no changes in plasma VEGF and sVEGFR2.…”
  12. 18232
  13. 18233

    Monocyte Recruitment to the Dermis and Differentiation to Dendritic Cells Increases the Targets for Dengue Virus Replication by Michael A. Schmid (638218)

    Published 2014
    “…Further, we show that ∼100-fold more hematopoietic cells in the dermis were DENV-infected compared to Langerhans cells in the epidermis. …”
  14. 18234

    Data Sheet 1_Application of compost amended with biochar on the distribution of antibiotic resistance genes in a soil–cucumber system—from the perspective of high-dose fertilizatio... by Shuai Shi (333614)

    Published 2025
    “…Compared with those in the control treatment group, the absolute abundance of ermB, ermT, gyrA, qnrS, tetC, and intI1 decreased by 6–100% in the soil of the SBTC group. …”
  15. 18235
  16. 18236

    Image 1_Bilateral dorsolateral prefrontal cortex high-frequency transcranial magnetic stimulation for consciousness recovery after traumatic brain injury: a case series.tif by Chun-Hung Chang (760118)

    Published 2025
    “…SPECT revealed reduced hypoperfusion in the bilateral frontal lobes, decreasing from 51% to 40% in Patient A and from 33% to 30% in Patient B. …”
  17. 18237

    Supplementary Material for: Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Te... by Akizawa T. (3588626)

    Published 2019
    “…<b><i>Methods:</i></b> Subjects receiving a stable dose of an erythropoiesis-stimulating agent were randomized to receive once-daily enarodustat at a dose of 2, 4, or 6 mg or placebo in a double-blind manner for 6 weeks (Period 1) followed by 24-week open treatment with enarodustat, adjusted in the range of 2–8 mg to maintain Hb within a target range (10.0–12.0 g/dL; Period 2). …”
  18. 18238

    ETCO<sub>2</sub> in an animal undergoing two-lung, left-lung, and right-lung ventilations via a standard endotracheal tube during cardiopulmonary resuscitation. by Dong Hyun Ryu (5095394)

    Published 2018
    “…Immediately after the endotracheal tube was advanced into the right main bronchus (point E), ETCO<sub>2</sub> decreased to 12.5 mmHg and remained between 10.0 and 11.0 mmHg after stabilization.…”
  19. 18239

    Thyroxine Differentially Modulates the Peripheral Clock: Lessons from the Human Hair Follicle by Jonathan A. Hardman (714625)

    Published 2015
    “…Over 24 hours we found a significant reduction in protein levels of BMAL1 and PER1, with their transcript levels also decreasing significantly. …”
  20. 18240

    DataSheet1_Dynamic phenotypic shifts and M2 receptor downregulation in bladder smooth muscle cells induced by mirabegron.PDF by A. E. Muderrisoglu (19204042)

    Published 2024
    “…After 40 h, decreases occured in the presence of L-748,337, but not without L-748,337. …”